Endometriosis Ovary
Conditions
Keywords
endometrioma, sclerotherapy, ovarian reserve, antimüllerian hormone
Brief summary
Endometriosis affects 6-10% of women in childbearing age. It is a heterogeneous disease with three different forms: superficial endometriosis (peritoneal), ovarian endometrioma and deep pelvic endometriosis (subperitoneal). Surgical management of endometriomas is justified in cases of significant clinical symptoms (like pain), especially in cases of resistance to medical treatment. Currently, laparoscopic cystectomy surgery is the recommended technique to treat ovarian endometrioma. However, it is now well demonstrated that this surgery significantly reduces the ovarian reserve. Ethanol sclerotherapy is an alternative technique used to treat ovarian endometriomas. Several studies demonstrated the effectiveness and safety of this treatment, particularly in terms of preserving fertility. Regarding these reassuring data, many clinicians changed their practices and propose this technique as a first-line surgery. Ovarian reserve comprises two elements: size of the primordial follicle stock and quality of the ovocytes. Antimüllerian hormone (AMH) has been shown to be the best marker of fertility. The aim of this study is to observe changes in AMH levels after endometrioma sclerotherapy. This study is conducted in the Hospices Civils de Lyon, in 3 different sites.
Interventions
BIOLOGICALBlood test
additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No
Inclusion criteria
* Patient in childbearing age from 18 to 42 years. * Patient with uni- or bilateral endometrioma(s) without clinical and ultrasound criteria for ovarian carcinoma. * A sclerotherapy is programmed. * Patient affiliated to a social security scheme. * Patient who gave consent for this research.
Exclusion criteria
* doubt about the endometriotic origin of the cyst * suspect malignant ovarian disease. * Pregnant or breastfeeding patient. * Patient participating in other research with an exclusion period still in progress at the time of inclusion or those included in interventional research that interferes with the study protocol. * Patient deprived of liberty by judicial or administrative decision. * Patient (≥ 18 years old) under legal protection or unable to give consent. * Patient does not speak French.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AMH level | 3 months (+/-15 days) after endometrioma sclerotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AMH level | 12 months (+/-15 days) after endometrioma sclerotherapy | — |
| Endometrioma recurrence | 3 months (+/-15 days) after endometrioma sclerotherapy | New endometrioma (≥ 2 cm) unilateral or bilateral, single or multiple |
Countries
France
Outcome results
None listed